Friedberg Ezra M 4
4 · Chromocell Therapeutics Corp · Filed Feb 23, 2024
Insider Transaction Report
Form 4
Friedberg Ezra M
Director
Transactions
- Exercise/Conversion
Common Stock
2024-02-21$4.80/sh+6,992$33,562→ 520,719 total(indirect: By LLC) - Exercise/Conversion
Common Stock
2024-02-21$4.80/sh+13,649$65,515→ 513,727 total(indirect: By LLC) - Conversion
Secured Convertible Promissory Note
2024-02-21−65,513.61→ 0 total(indirect: By LLC)Exercise: $4.80From: 2024-02-21Exp: 2024-02-29→ Common Stock (13,649 underlying) - Conversion
Secured Convertible Promissory Note
2024-02-21−33,136→ 0 total(indirect: By LLC)Exercise: $4.80From: 2024-02-21Exp: 2024-03-01→ Common Stock (6,992 underlying)
Footnotes (3)
- [F1]The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).
- [F2]Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.
- [F3]Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.